MaxCyte, Inc. (MXCT)

NMS – Цена в реальном времени. Валюта: USD

1.24

-0.03 (-2.36%)

При закрытии: Jun 26, 2026, 4:00 PM EDT

1.17

-0.07 (-5.65%)

После закрытия: Jun 26, 2026, 6:49 PM EDT

13.05.2026

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

13.05.2026

MaxCyte Q1 Earnings Call Highlights

MaxCyte NASDAQ: MXCT reported lower first-quarter revenue compared with the prior year, as management said discontinued SPL programs and inventory management by its largest customer weighed on core revenue, while milestone revenue from a registrational-stage program helped offset part of the decline.

12.05.2026

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

MaxCyte, Inc. (MXCT) came out with a quarterly loss of $0.04 per share versus the Zacks Consensus Estimate of a loss of $0.1. This compares to a loss of $0.1 per share a year ago.

12.05.2026

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

First quarter 2026 total revenue of $9.7 million, including $6.2 million of core revenue and $3.4 million of SPL Program-related revenue Reiterates 2026 revenue guidance of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million MaxCyte's Board authorized a $10 million share repurchase program ROCKVILLE, Md., May 12, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced its first quarter ended March 31, 2026 financial results and reiterated its 2026 guidance.

29.04.2026

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

ROCKVILLE, Md., April 29, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc., (NASDAQ: MXCT), a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it will release financial results for the first quarter 2026 after the U.S. market close on Tuesday, May 12th, 2026. Company management will host a conference call to discuss financial results at 4:30 p.m. Eastern Time.

31.03.2026

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

ROCKVILLE, Md., March 31, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, reported today that Compensation Committee of the Board of Directors of MaxCyte granted inducement awards in the form of stock options to purchase an aggregate of 375,000 shares of MaxCyte's common stock and a service-based restricted stock unit (“RSU”) award with respect to 187,500 shares of MaxCyte's common stock to Parmeet Ahuja in connection with his appointment as Chief Financial Officer of MaxCyte.

25.03.2026

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

Видео

No Data

There is no data to display

Пресс-релизы

12.05.2026

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

31.03.2026

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

24.03.2026

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

Fourth quarter 2025 total revenue of $7.3 million at the top of the range of previous preliminary announcement Full year 2025 revenue of $33.0 million, at the top of the range of previous preliminary announcement Total cash, cash equivalents and investments were $155.6 million as of December 31, 2025. Expects to end 2026 with at least $136 million in t otal cash, cash equivalents and investments Expects 2026 revenue of $30-32 million; with Core revenue of $25-27 million and Strategic Platform License (SPL) Program-related of $5 million ROCKVILLE, Md.

23.03.2026

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

ROCKVILLE, Md., March 23, 2026 (GLOBE NEWSWIRE) -- MaxCyte, Inc. (Nasdaq: MXCT), a leading cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of next-generation cell therapeutics, today announced that it has appointed Parmeet Ahuja as Chief Financial Officer, effective March 30, 2026. Mr. Ahuja succeeds Douglas Swirsky, who is transitioning from the role as previously announced in November 2025.

MaxCyte, Inc. (MXCT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

MaxCyte, Inc. (MXCT)

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

MaxCyte Q1 Earnings Call Highlights

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

MaxCyte Q1 Earnings Call Highlights

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

Search stocks

MaxCyte, Inc. (MXCT)

Получите доступ ко всем премиум-функциям лучшего инструмента для анализа акций

Finranks

Компания

Контакты

Мы в соцсетях

MaxCyte, Inc. (MXCT)

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

MaxCyte Q1 Earnings Call Highlights

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer

MaxCyte, Inc. (MXCT) Q1 2026 Earnings Call Transcript

MaxCyte Q1 Earnings Call Highlights

MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MaxCyte to Report First Quarter 2026 Financial Results on May 12, 2026

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte, Inc. (MXCT) Q4 2025 Earnings Call Transcript

Видео

No Data

Пресс-релизы

MaxCyte Reports First Quarter 2026 Financial Results and Reiterates Full Year 2026 Guidance

MaxCyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

MaxCyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Full Year 2026 Guidance

MaxCyte Appoints Parmeet Ahuja as Chief Financial Officer